Phase 3 original market intelligence · August 21, 2026

Urolithin A Product Database 2026

Expanded from a simple product list into a market-intelligence dataset covering 16 consumer products, formats, dose options and ingredient benchmarks. The database now separates price, testing transparency, evidence match and formula complexity rather than pretending one score can answer everything.

Download Phase 3 CSV

Urolithin A Phase 3 product intelligence database

Phase 3 snapshot

MARKET

16 entries

8 current full-size consumer products plus format, dose-option and ingredient benchmarks.

DOSE

500–1,200 mg

Verified stated Urolithin A range. Median across captured dose records: 500 mg.

AUDITABILITY

13/16

Entries scoring at least 4/10 on testing transparency; 2 expose a directly visible COA in the reviewed source.

The market is not really “500 mg vs 500 mg”

Phase 3 makes one pattern unusually clear: 500 mg is common, but product propositions are not interchangeable. Timeline sells 500 mg of the branded Mitopure ingredient in three consumer formats with human clinical positioning. Naturecan and Double Wood occupy a more conventional single-ingredient market. ProHealth uses 500 mg StanYouth Urolithin A plus pomegranate and muscadine precursors. Codeage uses 500 mg Urolithin A inside a multi-active formula with resveratrol, betaine and CoQ10.

That is why the database now treats dose, formulation, evidence and transparency as separate axes. Otherwise every 500 mg bottle ends up looking identical, which is convenient for a spreadsheet and useless for a buyer.

Full Phase 3 comparison table

Product	Entry type	Category	UA dose	Serving	Price	Cost / 500 mg	Transparency	Testing	Evidence Match	Value	Complexity	Source
Timeline Mitopure Softgels	Consumer product	Branded Urolithin A	500 mg	2 softgels	$99.00	$99.00	8/10	6/10	10/10	3.0/10	1/5	Source
Timeline Mitopure Powder	Consumer product	Branded Urolithin A	500 mg	1 sachet	$99.00	$99.00	8/10	6/10	10/10	3.0/10	1/5	Source
Timeline Mitopure Gummies	Consumer product	Branded Urolithin A	500 mg	2 gummies	$99.00	$99.00	8/10	6/10	10/10	3.0/10	1/5	Source
Timeline Mitopure Softgels Sample	Trial-size format	Branded Urolithin A	500 mg	2 softgels	Not captured	Not captured	7/10	6/10	10/10	—	1/5	Source
Timeline Mitopure Powder Sample	Trial-size format	Branded Urolithin A	500 mg	1 stickpack	Not captured	Not captured	7/10	6/10	10/10	—	1/5	Source
Timeline Mitopure Gummies Sample	Trial-size format	Branded Urolithin A	500 mg	2 gummies	Not captured	Not captured	7/10	6/10	10/10	—	1/5	Source
Codeage Liposomal Urolithin A	Consumer product	Multi-active / liposomal	500 mg	2 capsules	Not captured	Not captured	7/10	2/10	6/10	—	4/5	Source
ProHealth Longevity Full Spectrum Urolithin A	Consumer product	Multi-active / precursor blend	500 mg	2 capsules	$79.95	$79.95	10/10	9/10	6/10	5.3/10	4/5	Source
Naturecan Urolithin A	Consumer product	Single-ingredient	500 mg	1 capsule	$40.49	$40.49	9/10	8/10	8/10	9.9/10	1/5	Source
Double Wood Urolithin A	Consumer product	Single-ingredient	500 mg	Not captured	$39.95	$39.95	7/10	4/10	8/10	10.0/10	1/5	Source
DoNotAge Urolithin A - 500 mg/day option	Dose option	Single-ingredient / dose option	500 mg	Daily option	Not captured	Not captured	2/10	0/10	8/10	—	1/5	Source
DoNotAge Urolithin A - 1,000 mg/day option	Dose option	Single-ingredient / high-dose option	1000 mg	Daily option	Not captured	Not captured	2/10	0/10	8/10	—	1/5	Source
Renue By Science Urolithin A+	Consumer product	Capsule product	Not captured	2 capsules	Not captured	Not captured	4/10	6/10	4/10	—	2/5	Source
Nature's Fusions Nutri Urolithin A	Marketplace consumer product	Single-ingredient	500 mg	1 capsule	Not captured	Not captured	5/10	4/10	8/10	—	1/5	Source
Urolithin A+ Urolithin A 1200 mg	Marketplace consumer product	Single-ingredient / high-dose	1200 mg	1 vegetarian capsule	Not captured	Not captured	6/10	6/10	6/10	—	1/5	Source
Bonerge StanYouth Urolithin A Raw Ingredient	Ingredient benchmark	Branded raw ingredient	Not captured	Bulk ingredient	Not captured	Not captured	5/10	4/10	8/10	—	1/5	Source

Phase 3 data tools

Urolithin A Value Index

Normalized cost comparisons only where verified price and active dose make the math defensible.

Testing Transparency Report

COA visibility, third-party testing and certification compared independently from dose.

Evidence Match Report

Distinguishes finished-product/branded-ingredient evidence from generic ingredient borrowing.

Methodology

Official manufacturer sources are preferred. Marketplace and independent product-data sources are explicitly labeled rather than silently treated as equal. Missing values remain missing. Scores describe auditability, product-to-evidence mapping and commercial structure; they do not predict personal health outcomes.

Read the methodology.

Why the database exists

Narrative product reviews are hard to audit. The Phase 3 database converts the market into explicit fields for dose, price, testing, ingredient identity, evidence match, certifications, and formula complexity.

What is included

The current dataset includes full-size consumer products, Timeline format variants, dose options, marketplace products, and a branded raw-ingredient benchmark.

Why entry type matters

A full-size consumer SKU, a trial-size format, a dose option, and a raw ingredient are not the same commercial object. Phase 3 labels them separately so the comparison does not quietly mix categories.

Why missing data stay missing

When a current source does not expose a price, dose, COA, or certification, the database records the gap rather than filling it from memory or assumptions.

How to read Transparency

Transparency measures auditability: dose disclosure, serving clarity, price, testing, COA access, certification, and ingredient identity.

How to read Value

Value applies only where current price and dose make a cost-per-500 mg comparison defensible.

How to read Evidence Match

Evidence Match distinguishes a direct branded human-evidence relationship from generic ingredient-level borrowing.

How the database will evolve

Future phases can expand brand coverage, historical price tracking, testing-document freshness, subscriptions, refund policies, and finished-formula human-study fields.

Update trigger 1

For Urolithin A Product Database 2026, the conclusion should remain open to revision. New human trials, product reformulations, new COAs, certification changes, updated prices, and newly disclosed testing can all alter the commercial comparison. The goal is not to manufacture a permanent winner, but to show the evidence and product facts clearly enough that a reader can see why the conclusion was reached.